

NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

Room: Churchill B

APRIL 30, 2011 – 9:00 A.M. - 3:30 P.M.

CHAIR: GAVIN STUART

(3:30 A.M. – 4:30 P.M. EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- *To review the results of recent clinical trials in gynecologic oncology and to enhance understandings of the trials' results with respect to intervention adoption.*
- *To review aspects of standard care of patients with gynecologic cancer specifically as these practices relate to new NCIC CTG priority initiatives (e.g., ovarian cancer [first line therapy; therapy for platinum-resistant disease], cervical cancer).*
- *To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gynecologic cancers.*
- *To review QoL outcomes and the implications of adopting trial results (e.g., EN.5) and to discuss QoL methodological issues as these relate to gynecologic cancers.*

9:00 a.m.	<u>GYNE COMMITTEE – WELCOME</u>	G. Stuart/R. Meyer
	Introduction of guests Overview of activity, opportunities and the current environment of NCIC CTG clinical trials	
9:15 a.m.	<u>IND ACTIVITY</u>	H. Hirte
9:45 a.m.	<u>GYNE COMMITTEE LIAISONS/REPS REPORTS</u>	CRA/Pharm/Lay/Econ./QoL
10:15 a.m.	BREAK	
10:35 a.m.	<u>GYNE CORRELATIVE SCIENCE & TUMOUR BIOLOGY WORKING GROUP REPORT</u>	A. Mes-Masson
10:50 a.m.	<u>ENDOMETRIUM</u>	
	→ Phase III - EN5 (QoL & SAQ analysis) - EN7/PORTEC 3 - EN8	T. Whelan/D. Tu/H. Lukka P. Bessette/A. Fyles R. Meyer
	→ IND Studies - IND.192 (deforolimus)	H. Hirte/E. Eisenhauer

